F343 clone 3	
    			    			
                UNEWi023-B            
            
        General
Cell Line | 
					|
| hPSCreg name | UNEWi023-B | 
| Cite as: | UNEWi023-B (RRID:CVCL_IT89) | 
| Alternative name(s) | 
									 
	F343 clone 3	 
							 | 
						
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | 
							 | 
					
| Last update | 10th September 2025 | 
| User feedback | |
Provider | 
					|
| Generator | 
							University of Newcastle (UNEW)														    								 
    									Contact:
    									 
    																				Institute of Genetic Medicine  | 
					
| Owner | Institute of Genetic Medicine | 
| Distributors | |
| Derivation country | United Kingdom | 
External Databases | 
						|
| BioSamples | SAMEA4567587 | 
| Cellosaurus | CVCL_IT89 | 
| Wikidata | Q54991168 | 
							    
							General Information | 
					|
| Projects | |
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                                 Research use: allowed 
                                                                                    Clinical use: allowed 
                                                                                    Commercial use: allowed 
                                                                         | 
                            
Donor Information
General Donor Information | 
					|
| Sex | female | 
| Age of donor (at collection) | 85-89 | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | No disease was diagnosed.
																	 | 
					
Donor Relations | 
							|
| Other cell lines of this donor | |
External Databases (Donor) | 
						|
| BioSamples | SAMEA4567586 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | No | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes | 
| Is there other documentation provided to the donor for consenting purposes? | No | 
| Confirm that consent was obtained by a qualified professional | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No | 
| * Does consent pertain to a specific research project? | Yes | 
| Details on restriction to research project | Research use restricted to Retinal Degeneration and Dystrophies | 
| Does consent permit unforeseen future research, without further consent? | Yes | 
| Does consent expressly prevent development of commercial products? | No | 
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No | 
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
Does consent permit research by | |
| an academic institution? | Yes | 
| a public organisation? | Yes | 
| a non-profit company? | Yes | 
| a for-profit corporation? | Yes | 
| Does consent expressly permit collection of genetic information? | Yes | 
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | Yes | 
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No | 
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | North East - Newcastle & North Tyneside 1 Research Ethics Committee | 
| Approval number | 11/NE/0294 | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes | 
| Name of accrediting authority involved? | North East - Newcastle & North Tyneside 1 Research Ethics Committee | 
| Approval number | 11/NE/0294 | 
| Do you have obligations to third parties in regard to the use of the cell line? | No | 
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General | 
						|
| Source cell type | 
										
				
	
			 A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative. 
	
									 | 
							
| Source cell origin | 
										
				
	
			 Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis. 
	
			Synonyms 
		
  | 
							
| Age of donor (at collection) | 85-89 | 
| Passage number reprogrammed | P4 | 
Reprogramming method | 
						|
| Vector type | Non-integrating | 
| Vector | Sendai virus | 
| Genes | |
| Is reprogramming vector detectable? | 
										 No 									 | 
								
| Methods used | 
										 
	PCR	 
									 | 
								
Vector free reprogramming | 
						|
Other | 
						|
| Selection criteria for clones | Based on morphology, growth rate and expression of SSEA4 and NANOG | 
| Derived under xeno-free conditions | 
								 No 							 | 
						
| Derived under GMP? | 
								 No 							 | 
						
| Available as clinical grade? | 
								 No 							 | 
						
Culture Conditions
| Surface coating | Matrigel/Geltrex | 
| Feeder cells | 
															 No 														 | 
						
| Passage method | 
								Enzyme-free cell dissociation
								
																											 
											EDTA										 
																	
							 | 
						
| O2 Concentration | 20 % | 
| CO2 Concentration | 5 % | 
| Medium | 
								mTeSR™ 1		
		
								 | 
						
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| NANOG | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-60 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-1 | 
											 No 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-4 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                
Microbiology / Virus Screening | 
						|
| HIV 1 | Negative | 
| HIV 2 | Negative | 
| Hepatitis B | Negative | 
| Hepatitis C | Negative | 
| Mycoplasma | Negative | 
Certificate of Analysis | 
					|
| Is there a certificate of analysis available? | 
							 Yes 
																
		
															
														
								Passage:
								P9							 
													 | 
					
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
												No clinically significant imbalance was detected
											 
																				
																															
											Passage number: P9											 
																															
											Karyotyping method:
											Molecular karyotyping by SNP array											
											 
																			http://  | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.